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ABSTRACT
The frequent occurrence of genital herpes continues to be a serious clinical problem. Although not
life threatening, the physical symptoms of the disease, and the ensuing psychosocial complications,
can be overwhelming to patients. The life cycle of the herpes simplex virus is complex, comprising
multiple stages. Following infection, the virus establishes life-long latency in its host and can reac-
tivate at any time as a recurrent infection. Successful management of genital herpes simplex infec-
tions involves patient education and psychological support, as well as antiviral agents. The antiviral
agent famciclovir has been shown to shorten the course and decrease the severity of episodes of
recurrent genital herpes. In addition, famciclovir has been shown to be effective in suppressing
recurrent genital herpes. A review of the clinical experience with famciclovir in the treatment of
genital herpes is presented. Infect. Dis. Obstet. Gynecol. 6:38-43, 1998. (C) 1998 Wiley-Liss, Inc.
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ore than 45 million people in the. United
States are infected with the herpes simplex
virus (HSV) type 2 (HSV-2), the primary causative
agent of genital herpes; an additional 500,000
people become infected each year. 1,z The pre-
dominance of HSV-2 antibodies among those over
12 years of age is almost 22%. 2 Although HSV type
(HSV-1) infection is associated primarily with oral
herpes, it is being increasingly linked to genital
disease.3 The astounding prevalence of this sexu-
ally transmitted disease suggests the need for bet-
ter clinical management of genital herpes, includ-
ing appropriate treatment with antiviral agents.
The HSV life cycle is complex, consisting of five
stages: primary mucocutaneous infection, acute in-
fection of nerve ganglia, establishment of life-long
latency, reactivation, and recurrent infection (Fig-
ure 1).4 Exposure to HSV at mucosal surfaces or
abraded skin permits entry of the virus into epider-
mal and dermal cells and the initiation of viral rep-
lication,s Following primary infection, which can
be symptomatic or asymptomatic, the virus travels
to the neuronal nuclei in the dorsal root ganglia,
where it remains latent for indefinite periods.4 The
ability to persist in cells indefinitely, escaping
elimination by the host’s immune mechanisms, is
one of the most perplexing aspects of the herpes-
viruses.6
Patients with a first episode of genital herpes
may have either a true primary infection or an ini-
tial genital HSV-2 infection (nonprimary first epi-
sode). Symptomatic true primary infections are
typically severe and occur in seronegative individu-
als. Patients with nonprimary, first-episode HSV-2
infection have preexisting HSV-1 antibodies and
typically have a milder clinical presentation. Al-
though the diagnosis of HSV infection is usually
based on clinical signs and symptoms, most genital
HSV infections are not clinically apparent. Patients
can have atypical lesions or be asymptomatic. Pa-
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Fig. I. Herpes simplex virus cycle. There are five stages to
the herpes simplex virus life cycle. Stage I: Primary muco-
cutaneous infection of a susceptible individual and onset of
primary infection. Stage 2: After viral replication at the site
of inoculation, HSV infects the terminal branches of sensory
endings to the skin and is transported to the cell body of
sensory ganglia. Stage 3: At resolution of primary infection
viral replication is shut off and HSV establishes life-long
latency. Stage 4: Reactivation from the latent stage is trig-
gered and HSV is released from infected ganglia to reestab-
lish active infection. Stage 5: Recurrent infection ensues.
tients may also experience the reactivation of a pre-
viously asymptomatic genital herpes infection.
Factors responsible for the reactivation of the
herpesvirus and the onset of recurrent genital her-
pes infection are not well understood, although
emotional stress, sexual intercourse, menstruation,
and pregnancy may play a role.4-6 When reactiva-
tion is triggered, the virus is released from infected
dorsal root ganglia to reestablish active infection. 7
Recurrences are shorter and less intense than pri-
mary infections and are generally more severe in
women than in men. 7’8 In addition, while men ap-
pear to have a higher rate of symptomatic recur-
rence, asymptomatic recurrence is more frequent
in women,s,9 Women infected with HSV-2 also re-
quire careful gynecological management, including
frequent Pap tests, for the remainder of their lives
because HSV-2 antibodies have been associated
with cytological abnormalities of the cervix,z,4,6
Recurrence rates of HSV infections vary among
individuals and within the same individual,s Im-
mune competence appears to be crucial in the bal-
ance between latency and reactivation of the vi-
rus.s’7 In patients with symptomatic, first-episode
genital HSV-2, recurrence rates are high: four or
more per year in about 89% of patients within one
year of a first-episode HSV-2 infection. 8
Although not life threatening in the immuno-
competent patient, genital herpes is associated
with long-term negative sequelae. Psychological
and emotional complications are important aspects
of the long-term morbidity of HSV infections.6
The unpredictability of recurrent episodes and
their effect on interpersonal relationships can have
a substantial negative impact on a patient’s quality
of life. Palliative and supportive measures remain
the cornerstone of therapy for genital herpes, with
psychological support and patient education being
key elements of disease management. However,
these supportive measures do not treat the infec-
tion.4
In recent years, the development of safe and
effective antiviral agents has improved the man-
agement of HSV. Although there is no drug that
permanently destroys HSV, antiviral agents inhibit
the virus by interacting with the viral-coded DNA
polymerase, ending subsequent viral replication.4,7
The challenge of antiviral therapy lies not only in
treatment of symptoms during first and recurrent
episodes, but also in the long-term suppression of
the herpesvirus for patients with frequent recur-
rences.
PHARMACOKINETICS OF
ANTIVIRAL THERAPIES
Acyclovir (Zovirax(R), Glaxo Wellcome, Inc., Re-
search Triangle Park, NC) has been the drug of
choice for HSV infections for well over a decade. A
large number of clinical trials have documented its
safety and efficacy in various patient populations.1
Acyclovir is an acyclic nucleoside analog that in-
hibits DNA replication. It is activated to its triphos-
phate form, incorporates into viral DNA, and ter-
minates viral DNA synthesis. Acyclovir triphos-
phate has limited stability when acyclovir is
removed from the culture medium and a short in-
tracellular half-life in vitro (less than one hour). 11
In addition, the bioavailability of acyclovir admin-
istered orally is 10% to 20%. le
Valacyclovir (Valtrex(R), Glaxo Wellcome, Inc.),
the L-valyl ester and prodrug of acyclovir, has more
recently been developed for the treatment of acute
recurrent genital herpes. It has a bioavailability of
55%; lz however, since valacyclovir is the prodrug,
once absorbed it has the same pharmacokinetic
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Fig. 2. Absorption of famciclovir. After ingestion, famciclovir has good stability in duodenal contents. Enzymes in the
intestinal wall begin converting famciclovir to the pharmacologically active penciclovir, with most of the process occurring and
completing in the liver. Once conversion is complete, penciclovir is rapidly circulated through the body via the bloodstream.
(Figure from Vere Hodge et al.,s with permission.)
characteristics as acyclovir. Thus, the active form of
valacyclovir also has limited stability and a short
intracellular half-life in vitro (less than one hour in
HSV-2-infected cells). 11
Famciclovir (Famvir(R), SmithKline Beecham
Pharmaceuticals, Philadelphia, PA), the oral form
of penciclovir, a guanosine nucleoside analog, has
been introduced into clinical use for the manage-
ment of acute herpes zoster and more recently for
the treatment or suppression of recurrent episodes
of genital herpes. 13,14 Famciclovir is well absorbed
and rapidly converted to penciclovir by a series of
metabolic steps in the intestinal wall and liver (Fig-
ure 2). 15-17 Once penciclovir enters herpesvirus-
infected cells, it is rapidly converted to its active
metabolite, penciclovir triphosphate, which is, in
part, dependent on the viral enzyme thymidine ki-
nase, and stops subsequent replication of the vi-
rtls. ll’17-z0 The intracellular half-life of penciclovir
triphosphate in vitro is 20 hours in HSV-2-infected
cells (Table 1). 11’16
Little unchanged famciclovir is found in the
plasma, and the overall bioavailability of penciclo-
vir from oral famciclovir is approximately 77%
TABLE I. Pharmacokinetic overview offamciclovir
Penciclovir
Bioavailability (%) 77
Dose proportionality Yes
Plasma half-life (hr) 2-3
Rate of phosphorylation High
Intracellular half-life (hr)
HSV-I infected cells 10
HSV-2 infected cells 20
Excretion Renal
aOral formulation of famciclovir.
bin vitro data.
CMeasured in vitro as the triphosphate metabolites.
(Table 1).zl The bioavailability of penciclovir is not
affected by the presence of food.zz,z3 No clinically
significant alterations in pharmacokinetics of pen-
ciclovir were observed following single versus re-
peat doses of 500 mg of famciclovir or single-dose
administration of 500 mg of famciclovir after pre-
treatment with multiple doses of drugs known to
inhibit hepatic oxidative enzymes (cimetidine and
allopurinol) or to have narrow therapeutic ranges
(theophylline and digoxin),z4 In addition, no clini-
cally significant pharmacokinetic interactions be-
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tween 500-mg, single-dose therapy with famciclo-
vir and 200-mg of zidovudine (Retrovir(R), Glaxo
Wellcome, Inc.) were found when these agents
were coadministered to immunocompromised pa-
tients.2s
CLINICAL EXPERIENCE WITH FAMCICLOVIR
Safety
Since its introduction, famciclovir has been pre-
scribed more than 2.7 million times worldwide
(Data on file at SmithKline Beecham Pharmaceu-
ticals). In integrated safety evaluations of more
than 5,000 patients participating in clinical trials
with famciclovir, the most common adverse ex-
periences observed in a similar proportion of pa-
tients receiving either famciclovir or placebo were
headache (-10%), nausea (-5%), and diarrhea
(-3%).26,27 Withdrawal from famciclovir treatment
due to an adverse event has occurred in less than
1% of patients.26,27 In addition, no consistent asso-
ciation has been observed between famciclovir
treatment and any abnormal laboratory test.26,27
Efficacy
The efficacy of famciclovir in patients with recur-
rent genital herpes was evaluated in two dose-
ranging, randomized, double-blind studies. 14,2s In
these studies, 1,000 patients received famciclovir in
125-mg, 250-mg, or 500-mg doses or a placebo
twice daily for five days beginning within six hours
of lesion onset (clinic initiated) or prodromal/other
signs or symptoms of an outbreak (patient initi-
ated). The duration of viral shedding, cessation of
all symptoms (collectively defined as lesion tender-
ness, pain, itching, burning, and tingling), and time
to lesion healing was significantly improved at each
dose of famciclovir, compared with placebo. 14,2s
In the clinic-initiated study, the duration of viral
shedding was reduced by more than 50% (1.6 days
for 125-mg of famciclovir versus 3.4 days for pla-
cebo [P 0.0001]). Median time to complete heal-
ing was shorter for patients receiving 125-mg doses
of famciclovir, compared with placebo-treated pa-
tients (P 0.0009).28 In the patient-initiated study,
the duration of viral shedding was reduced by al-
most two days with famciclovir treatment, from a
median of 3.3 days with placebo to a median of 1.7
days with 125 mg of famciclovir. Of the patients
who were viral-culture-negative prior to initiation
of therapy, 73% of those treated with famciclovir
remained culture-negative, compared with 46% of
patients receiving placebo. 14 The median time to
loss of all symptoms was 3.2 days for patients
treated with 125 mg of famciclovir, compared with
3.7 days for placebo-treated patients (P < 0.01
based on a hazard ratio of 1.6). 14 Median time to
complete healing was 3.8 days for patients receiv-
ing 125 mg of famciclovir, compared with 4.8 days
for placebo-treated patients. 14
The efficacy of famciclovir has also been evalu-
ated for the suppression of genital herpes. Women
(n 375) with a history of six or more episodes of
recurrent genital herpes per year were treated with
famciclovir (125 mg, once or twice daily; 250 mg,
once or twice daily; or 500 mg, once daily) or pla-
cebo for four months, z9 All doses of famciclovir
were effective in suppressing HSV recurrences;
however, famciclovir in doses of 250 mg, twice
daily, was clearly the most effective,z9 In addition,
the proportion of patients who remained free of
HSV recurrences during the 120-day study in-
creased from 48% in the placebo-treated group to
90% in patients receiving famciclovir in doses of
250 mg, twice daily (P < 0.001).z9
The meta-analysis of two year-long clinical tri-
als, in which 369 patients were enrolled (236 re-
ceiving famciclovir, 250 mg, twice daily; 133 receiv-
ing placebo), showed that 80% fewer genital herpes
outbreaks occurred in famciclovir-treated patients
(median number of recurrences was 1) than in pla-
cebo-recipients (median number of recurrences
was 4.9) (Data on file, SmithKline Beecham Phar-
maceuticals). These and other studies show that
once-daily dosing is less effective at preventing
outbreaks than is multidosing,z9-31
The efficacy of famciclovir for the treatment of
first-episode genital herpes was evaluated in three
studies, which enrolled a total of 951 patients. In
two of these studies, famciclovir, 250 mg, 500 mg,
and 750 mg, three times for a day for five days, was
compared with acyclovir, 200 mg, five times a day
for five days; in the third study, famciclovir, 125
mg, 250 mg, and 500 mg, three times a day for 10
days, was compared with acyclovir, 200 mg, five
times a day for 10 days.3z No significant differences
between famciclovir and acyclovir were seen in the
times to cessation of viral shedding, complete heal-
ing, or loss of all symptoms, suggesting that three
times daily dosing of famciclovir is as effective as
acyclovir five times daily in treatment of initial epi-
sodes of genital herpes.
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Famciclovir may also impact HSV latency and/or
subsequent reactivation. Preclinical studies have
shown that treatment with famciclovir was more
effective than valacyclovir in reducing the inci-
dence of clinical manifestations of HSV-1 infec-
tions in mice.33,34 In addition, the famciclovir-
treated mice showed markedly reduced evidence
of latent virus present in explanted ganglia.33,4
Based on these results, as well as preliminary clini-
cal data that support these observations, clinical
trials have been initiated to further examine the
effects of famciclovir on latency/reactivation after
administration to patients with first-episode genital
herpes.s
SUMMARY
Genital herpes, caused by HSV infection, is a
chronic and often debilitating disease. Life-long
persistence of the virus and unpredictability of
clinical recurrences cause both physical and psy-
chological sequelae that require long-term manage-
ment. Educational and psychological support are
important aspects in the management of genital
herpes. However, advances in antiviral therapy
have also played an important role.
Famciclovir represents a new advance in antivi-
ral therapy. Its pharmacokinetic profile exceeds
those of both acyclovir and valacyclovir. Studies
have shown that treatment with famciclovir re-
duces viral shedding, provides rapid resolution of
lesions, and relieves all symptoms of recurrent
genital herpes. 14,es Patients may have fewer psy-
chological problems coping with the disease if the
duration of viral shedding and uncomfortable
symptoms associated with genital herpes are re-
duced. Famciclovir has also been shown to be ef-
fective in those patients who require long-term
suppressive antiviral therapy. Finally, famciclovir is
effective in relieving the acute signs and symptoms
of first-episode genital herpes, and preclinical evi-
dence suggests it has the potential to be effective
in preventing life-long HSV latency or subsequent
reactivation following treatment of first episodes.
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